Members
First name: Baptiste Last name: Gaborieau Function: Post-Doc Researcher Position: Medical Doctor / Post-Doc Researcher Email: baptiste.gaborieau inserm.fr |
Research interest
My goal is to develop translational research, combining basic research with clinical research, and contributing to medical progress in the fight against infectious diseases through the use of bacteriophages.
Most of my work is based on models prevention and treatment of bacterial pneumonia due to Escherichia coli by phages.
I develop in collaboration with other French laboratories:
- an evolutionary approach to better understand the host spectrum of phages.
- pre-clinical approaches relating to the key elements for the effectiveness of the phage-therapy of the tripartite interaction between bacteria, bacteriophage and host (resistance, pharmacometry, immunity).
Education
Degree
2021 : M.D. Paris Descartes Medical School, Université de Paris Cité, France
2022 : PhD in Microbiology, Université de Paris Cité, France
2022 : PhD in Microbiology, Université de Paris Cité, France
Academic positions
2013-2019 : Resident, Paris Descartes Medical School, Université de Paris Cité, Assistance Publique-Hôpitaux de Paris, France
2022- : Chef de Clinique des Universités- Assitant Hospitalier, Intensive Care Unit, Hospital Louis Mourier, Université de Paris Cité, Assistance Publique-Hôpitaux de Paris, France
2022- : Chef de Clinique des Universités- Assitant Hospitalier, Intensive Care Unit, Hospital Louis Mourier, Université de Paris Cité, Assistance Publique-Hôpitaux de Paris, France
Research training (post doctoral)
2019-2022 : PhD student
* IAME U1137, Université de Paris Cité-INSERM, Paris France
* Bacteria, Bacteriophage, Host, Institut Pasteur, Paris, France
2017-2018 : Matser 2 Student, IAME U1137, Université de Paris Cité-INSERM, France
* IAME U1137, Université de Paris Cité-INSERM, Paris France
* Bacteria, Bacteriophage, Host, Institut Pasteur, Paris, France
2017-2018 : Matser 2 Student, IAME U1137, Université de Paris Cité-INSERM, France
List of the main publications
Gaborieau B, Debarbieux L
The role of the animal host in the management of bacteriophage resistance during phage therapy.
Current Opinion in Virology 2023, 58, 101290.
Weissfuss C, Wienhold SM, Bürkle M, Gaborieau B, Bushe J, Behrendt U, Bischoff R, Korf IHE, Wienecke S, Dannheim A, Ziehr H, Rohde C, Gruber AD, Ricard JD, Debarbieux L, Witzenrath M, Nouailles G
Repetitive Exposure to Bacteriophage Cocktails against Pseudomonas aeruginosa or Escherichia coli Provokes Marginal Humoral Immunity in Naïve Mice.
Viruses 2023, 15, 387.
Delattre R, Seurat J, Haddad F, Nguyen TT, Gaborieau B, Kane R, Dufour N, Ricard JD, Guedj J, Debarbieux L
Combination of in vivo phage therapy data with in silico model highlights key parameters for pneumonia treatment efficacy.
Cell Reports 2022, 39, 110825.
Ferran AA, Lacroix MZ, Gourbeyre O, Huesca A, Gaborieau B, Debarbieux L, Bousquet-Mélou A
The Selection of Antibiotic- and Bacteriophage-Resistant Pseudomonas aeruginosa Is Prevented by Their Combination.
Microbiology Spectrum 2022, 10, e0287422.
The role of the animal host in the management of bacteriophage resistance during phage therapy.
Current Opinion in Virology 2023, 58, 101290.
Weissfuss C, Wienhold SM, Bürkle M, Gaborieau B, Bushe J, Behrendt U, Bischoff R, Korf IHE, Wienecke S, Dannheim A, Ziehr H, Rohde C, Gruber AD, Ricard JD, Debarbieux L, Witzenrath M, Nouailles G
Repetitive Exposure to Bacteriophage Cocktails against Pseudomonas aeruginosa or Escherichia coli Provokes Marginal Humoral Immunity in Naïve Mice.
Viruses 2023, 15, 387.
Delattre R, Seurat J, Haddad F, Nguyen TT, Gaborieau B, Kane R, Dufour N, Ricard JD, Guedj J, Debarbieux L
Combination of in vivo phage therapy data with in silico model highlights key parameters for pneumonia treatment efficacy.
Cell Reports 2022, 39, 110825.
Ferran AA, Lacroix MZ, Gourbeyre O, Huesca A, Gaborieau B, Debarbieux L, Bousquet-Mélou A
The Selection of Antibiotic- and Bacteriophage-Resistant Pseudomonas aeruginosa Is Prevented by Their Combination.
Microbiology Spectrum 2022, 10, e0287422.
Exhaustive list of publications
2023
Gaborieau B, Debarbieux L
The role of the animal host in the management of bacteriophage resistance during phage therapy.
Current Opinion in Virology 2023, 58, 101290.
Weissfuss C, Wienhold SM, Bürkle M, Gaborieau B, Bushe J, Behrendt U, Bischoff R, Korf IHE, Wienecke S, Dannheim A, Ziehr H, Rohde C, Gruber AD, Ricard JD, Debarbieux L, Witzenrath M, Nouailles G
Repetitive Exposure to Bacteriophage Cocktails against Pseudomonas aeruginosa or Escherichia coli Provokes Marginal Humoral Immunity in Naïve Mice.
Viruses 2023, 15, 387.
2022
Delattre R, Seurat J, Haddad F, Nguyen TT, Gaborieau B, Kane R, Dufour N, Ricard JD, Guedj J, Debarbieux L
Combination of in vivo phage therapy data with in silico model highlights key parameters for pneumonia treatment efficacy.
Cell Reports 2022, 39, 110825.
Ferran AA, Lacroix MZ, Gourbeyre O, Huesca A, Gaborieau B, Debarbieux L, Bousquet-Mélou A
The Selection of Antibiotic- and Bacteriophage-Resistant Pseudomonas aeruginosa Is Prevented by Their Combination.
Microbiology Spectrum 2022, 10, e0287422.
2020
Le Breton C, Besset S, Freita-Ramos S, Amouretti M, Billiet PA, Dao M, Dumont LM, Federici L, Gaborieau B, Longrois D, Postel-Vinay P, Vuillard C, Zucman N, Lebreton G, Combes A, Dreyfuss D, Ricard JD, Roux D
Extracorporeal membrane oxygenation for refractory COVID-19 acute respiratory distress syndrome.
Journal of Critical Care 2020, 60, 10-12.
Torres-Garcia S, Di Pompeo L, Eivers L, Gaborieau B, White SA, Pidoux AL, Kanigowska P, Yaseen I, Cai Y, Allshire RC
SpEDIT: A fast and efficient CRISPR/Cas9 method for fission yeast..
Wellcome open research 2020, 5, 274.
2019
Ricard JD, Gaborieau B, Bernier J, Le Breton C, Messika J
Use of high flow nasal cannula for preoxygenation and apneic oxygenation during intubation..
Annals of translational medicine 2019, 7, S380.